NYSE - Delayed Quote USD

Prestige Consumer Healthcare Inc. (PBH)

70.47 +0.33 (+0.47%)
At close: April 26 at 4:00 PM EDT
70.47 0.00 (0.00%)
After hours: April 26 at 5:59 PM EDT
Key Events
Loading Chart for PBH
DELL
  • Previous Close 70.14
  • Open 69.94
  • Bid 70.03 x 800
  • Ask 70.10 x 800
  • Day's Range 69.89 - 70.75
  • 52 Week Range 52.90 - 75.31
  • Volume 153,225
  • Avg. Volume 243,207
  • Market Cap (intraday) 3.499B
  • Beta (5Y Monthly) 0.53
  • PE Ratio (TTM) --
  • EPS (TTM) -1.61
  • Earnings Date May 14, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date Dec 27, 2013
  • 1y Target Est 75.60

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

www.prestigebrands.com

560

Full Time Employees

March 31

Fiscal Year Ends

Recent News: PBH

Performance Overview: PBH

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PBH
15.11%
S&P 500
6.92%

1-Year Return

PBH
14.70%
S&P 500
25.26%

3-Year Return

PBH
57.26%
S&P 500
22.00%

5-Year Return

PBH
144.26%
S&P 500
74.29%

Compare To: PBH

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PBH

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    3.50B

  • Enterprise Value

    4.65B

  • Trailing P/E

    --

  • Forward P/E

    15.36

  • PEG Ratio (5yr expected)

    1.92

  • Price/Sales (ttm)

    3.09

  • Price/Book (mrq)

    2.19

  • Enterprise Value/Revenue

    4.10

  • Enterprise Value/EBITDA

    432.36

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -7.11%

  • Return on Assets (ttm)

    6.16%

  • Return on Equity (ttm)

    -4.91%

  • Revenue (ttm)

    1.13B

  • Net Income Avi to Common (ttm)

    -80.67M

  • Diluted EPS (ttm)

    -1.61

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    63.62M

  • Total Debt/Equity (mrq)

    75.82%

  • Levered Free Cash Flow (ttm)

    175.69M

Research Analysis: PBH

Analyst Price Targets

65.00 Low
75.60 Average
70.47 Current
84.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: PBH

Fair Value

70.47 Current
 

Dividend Score

0 Low
PBH
Sector Avg.
100 High
 

Hiring Score

0 Low
PBH
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
PBH
Sector Avg.
100 High
 

Research Reports: PBH

  • PBH: Raising target price to $75.00

    PRESTIGE CONSUMER HEALTHCARE has an Investment Rating of HOLD; a target price of $75.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     
  • PBH: Lowering target price to $71.00

    PRESTIGE CONSUMER HEALTHCARE has an Investment Rating of HOLD; a target price of $71.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     
  • PBH: Raising target price to $73.00

    PRESTIGE CONSUMER HEALTHCARE has an Investment Rating of HOLD; a target price of $73.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     
  • PBH: Rating increased to a HOLD

    PRESTIGE CONSUMER HEALTHCARE has an Investment Rating of HOLD; a target price of $56.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     

People Also Watch